One of the biggest names in cannabis research and development, Cannabis Science, Inc is a biotech company that creates cannabinoid-based formulations for a variety of medical conditions. Among these are eight types of cancer, autism, attention deficit hyperactivity disorder (ADHD), and other neurobehavioral disorders.
The company has two major programs on cannabinoid medicines. One is on CS-TATI-1, targeted for patients with drug-resistant HIV strains. The development of this product particularly looks at an HIV-related cancer called Epidemic AIDS-Related Kaposi Sarcoma. Meanwhile, the other program is on CS-S/BCC-1, producing cannabinoid-based extracts that can be applied topically on skin cancer lesions. The company has seen some success in patients who have self-administered this treatment, and is now discussing it with FDA specialists.
Aside from its scientific programs and innovations, Cannabis Science also produces online videos promoting education on medical marijuana. It has also been a partner of various key players in the marijuana industry, including the medical cannabis consulting firm Michigan Green Technologies and the medical dispensing solutions company Medbox.
Cannabis Science was founded in 2000 as National Healthcare Technology. In 2009, it was reestablished as Cannabis Science and then went into public trading, with a new drive to advance its research on the pharmaceutical potential of marijuana. The company’s present CEO is Dorothy H. Bray, PhD, who was formerly the Global Director of HIV Research at GlaxoSmithKline. Other Cannabis Science executives include Chad S. Johnson as COO, Robert Kane as CFO, and Richard Ogden, PhD as Chief Scientific Officer.
Based in Cannabis Science is being traded in the OTC market as CBIS and is valued at USD 61.64 M. It is listed under the Medical Laboratories & Research industry, in the Healthcare sector.
Cannabis Science, Inc
6946 North Academy Boulevard
Suite B #254
Colorado Springs, CO 80918
Phone: +1 (888) 889-0888
Fax: +1 (866) 943-5085
Yahoo! Finance: CBIS News
Latest Financial News for CBIS
IRVINE, CA, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it is entering a transition stage as trading of the Company’s shares is halted. Cannabis Science will continue to implement its corporate growth strategy and intends to resolve all outstanding regulatory reporting and filing requirements as it goes through its transition. “I can confirm that I found out yesterday that the trading of Cannabis Science’s shares has been halted by regulatory authorities - clearly the paperwork states ‘due to the financials not being filed as a fully-reporting issuer’. While this is not a favorable situation, we are already addressing this matter directly with the authorities to protect the interests of our shareholders and stakeholders,” states Raymond C. Dabney, President, C.E.O. and Co-Founder of Cannabis Science.
IRVINE, CA, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has signed a joint venture agreement with a Canadian public company, NHS Industries, Ltd. NHS Industries (CSE: (NHS), (NNHHF)). The group will focus on job creation, deliver and develop public and private access educational content, and research various delivery platforms for medical cannabinoid-related products and services, all based on the CBIS Economic Development Plan for Canada, (CBIS/CDN EDP). The new Canadian-based partnership will expand Cannabis Science’s existing operations into Canada through its CDN EDP.
IRVINE, CA, Aug. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is preparing to announce a number of exciting new partnerships and acquisitions as the Company prepares for a significant growth in revenue and positive cash flow from operations in key markets globally. The Company will be taking corporate actions to fast track this growth, including compiling the Company financials over the next quarter to achieve compliance with its fully reporting status requirements.
IRVINE, CA, Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has successfully completed reorganization of its European business to better align with the requirements of its customers, partners, and stakeholders. This move is expected to help improve the efficiency and effectiveness of CBIS’ European operations, and provide the necessary infrastructure to manage supply-chain logistics, new product development, and revenue growth. The Company’s activities, including cultivation, extraction, and manufacturing, will be headquartered in The Netherlands while all former Germany operations have been dissolved.
IRVINE, CA, July 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines and other products, is pleased to announce that its wholly-owned subsidiary, Cannabis Science Europe GmbH, has successfully completed testing and validation of its proprietary short-time vacuum distillation process for the purification and enhancement of cannabidiol (CBD) extract with high levels of Cannabidiolic Acid (CBDA) which subsequently is converted into purified water-soluble CBDA and CBD powder. The Company expects this new technology to drive sales growth with wholesale and retail customers internationally, subject to the jurisdictional regulatory constraints in targeted countries.